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2Abstract
Aminoacyl-tRNA synthetases are essential for the correct linkage of an amino acid to its
cognate tRNA. The accuracy of this reaction is key to the fidelity of protein synthesis.
Tractable, continuous assays are of value both in characterizing the functions of these
enzymes and their exploitation as drug targets. Therefore, we have exploited the hitherto
unexplored ability of these enzymes to consume the diadenosine nucleotide diadenosine
5’,5’’’ P1 P4 tetraphosphate (adenosine tetraphosphoadenosine (Ap4A)) with the concomitant
production of ATP in a pyrophosphate and amino acid dependent manner to develop such
an assay. We have used this assay to probe the stereo-selectivity of amino acid activation
by isoleucyl-tRNAIle and Valyl-tRNAVal synthetases and to identify analogues of intermediates
in their catalytic pathway that might facilitate simultaneous targeting of multiple synthetases.
Finally we report the utility of Ap4A based assays in the screening and subsequent
identification of inhibitors of these enzymes, where the kinetics of Ap4A utilization allow the
detection of inhibitors with nM to mM affinities.
Introduction
The ability of small molecules to distinguish between eukaryotic and prokaryotic protein
synthesis has provided the basis of antimicrobial activity for a number of clinically valuable
antibiotics1,2. This includes the antibiotic mupirocin, which is used therapeutically as a
topical agent targeting the active site of Gram positive isoleucyl-tRNAIle synthetase (IleRS)3-5,
preventing the formation of isoleucyl-tRNAIle. However, the lack of systemic efficacy of
mupirocin and its inactivity against Gram negative and TB infections6,7 as well as the rise of
mupirocin resistance in MRSA and MSSA3,8 has increased the need for new inhibitors
targeting this class of enzymes.
Many aminoacyl-tRNA synthetases (AaRSs) cannot bind the correct amino acid with
sufficient accuracy to ensure the fidelity of protein synthesis9. Therefore these enzymes
3have developed editing strategies to remove incorrectly aminoacylated intermediates and
mis-aminoacylated tRNAs in what are termed pre and post-transfer editing mechanisms.
These mechanisms are partitioned between the active site (pre-transfer) and a physically
distinct dedicated (post-transfer) editing domain10-14. Recent attempts to target the
interaction of tRNALeu with the post-transfer editing domain of leucyl-tRNALeu synthetase
(LeuRS) from Gram negative pathogens with small molecule boron inhibitors have been
abandoned because of the rapid onset of resistance in clinical trials due to mutation15. The
clinical efficacy of mupirocin compared to that of small molecule boron inhibitors highlights
the relative essentiality and mutability of the active site versus the post-transfer editing sites
of AaRSs and consequently their value as antibacterial targets particularly where
synthetases utilise more than one mechanism of editing(16,17). This weakness in targeting
post-transfer editing in prokaryotes is further illustrated by Escherichia coli LeuRS where
mutation of the post-transfer editing site unveils a pre-transfer-editing capability18.
All AaRSs share a mechanism involving activation of the cognate amino acid by
reaction with ATP to form a central aminoacyl-adenylate (Figure 1). AaRSs then catalyse
the attack of this central intermediate by tRNA to form the correct aminoacyl-tRNA product14.
However, in the absence of tRNA, these enzymes can catalyse the cleavage of this central
aminoacyl-adenylate by pyrophosphate. Consequently, [32P]-Pyrophosphate can be
employed to study pyrophosphate exchange into ATP which can be monitored as an output
(Figure 1 reaction 1)19. Alternatively, the formation of the aminoacyl-tRNA from the
aminoacyl-adenylate intermediate (Figure 1, reaction 2) can be followed in the presence of
radiolabelled amino acid by trichloroacetic acid precipitation of the radiolabelled
aminoacylated tRNA product19.
However, the utilization of radiolabels can be problematic, it precludes continuous
monitoring of AaRS activity and because of the costs of purchase and disposal, often
precludes high throughput and saturating substrate experiments 19. This and the success of
mupirocin suggest a significant advance in inhibitor screening could be leveraged by
4introduction of continuous non-radioactive assays that monitored AaRS catalysed aminoacyl
adenylate turnover. Furthermore, such an assay could also be applied more generally to
AaRS enzymology.
For many synthetases, the nucleophile attacking the aminoacyl-adenylate can also
be the oxygen atom appended to the J-phosphorous of a second molecule of ATP, instead
of pyrophosphate or tRNA, which attacks the D-phosphorus of the adenylate moiety of the
aminoacyl-adenylate. This results in the amino acid-dependent formation of Ap4A (Figure 1,
reaction 3)20-23.
Reversal of amino acid-dependent Ap4A formation by AaRSs, in the presence of
pyrophosphate would be expected to generate two molecules of ATP which could then be
detected by spectrophotometric, fluorometric or bioluminescent methodologies. This would
provide a viable alternative to [32P]-pyrophosphate exchange assays. Therefore, we
demonstrate here that amino acid, pyrophosphate and Ap4A dependent ATP generation can
be followed continuously by tractable spectrophotometric coupled assays that can be applied
to the now straightforward characterization of AaRS enzymology and for detection of
inhibitors of a number of these essential drug targets.
Results and Discussion
Requirement for the generation of novel AaRS assays. We initially identified the assay
partially developed by Roy24 as a starting point. Here, the pyrophosphate nucleophile
attacking the aminoacyl adenylate intermediate would exchange for the imidodiphosphate
moiety of 5'-adenylyl-EJ-imidodiphosphate (ADPNP) in the presence of the amino acid to
generate ATP that could then be assayed spectrophotometrically (Supporting Information
Figure 1 (Figure S1a)). This approach was flawed by the inability of Roy24 to show
dependence of the rates detected on pyrophosphate. Nevertheless we re-developed this
method to obtain a working assay that was applicable to E. coli and Streptococcus
5pneumoniae alanyl-tRNAAla and S. pneumoniae seryl-tRNASer synthetases (AlaRS and
SerRS) that we kinetically characterised (Table S1 and Figure S2a-i).
However we found this approach was limited by the inability of the class I IleRS and
valyl-tRNAVal synthetases (ValRS) from E. coli to utilise ADPNP (Figure S1b), as was also
found for the baker’s yeast enzymes by Friest et al.25. Furthermore, the low ADPNP KmApp of
E. coli AlaRS (4.8 ± 0.64 µM; Table S1) reduced the sensitivity of the assay to the detection
of competitive inhibitors. It is possible that this restriction of adenine nucleotide specificity is
related to the differential mode of ATP binding to class I and II synthetases14,26. To enable
access to the enzymology of both class I and II AaRSs, in the context of screening for small
molecule inhibitors with a high degree of sensitivity to hit detection, we sought another
potential adenylate based substrate to support pyrophosphate exchange activity.
Reversal of AaRS-catalysed Ap4A synthesis suggests an ATP release assay. All of the
synthetases discussed above have been observed to synthesise Ap4A where the aminoacyl
adenylate formed with the concomitant generation of pyrophosphate, would be cleaved by a
second molecule of ATP20-22. We investigated the reverse of this process where the
synthetase would catalyse the amino acid and pyrophosphate dependent
pyrophosphorolysis of Ap4A to form two molecules of ATP that could be continuously
monitored (Figure 2).
The assays based around the conversion of Ap4A to ATP require a detection system
that could distinguish between these phosphonucleotides and provide a read out of ATP in
the presence of a considerable excess of Ap4A. The ability of hexokinase to discriminate
between ATP and ATP analogues such as ADPNP24 and adenosine E methylene
triphosphate (Lloyd, unpublished) was therefore tested with respect to Ap4A. Here,
phosphorylation of glucose with ATP by hexokinase was coupled to oxidation of the resulting
glucose 6-phosphate to 6-phosphogluconate with reduction of NADP+ by glucose 6-
phosphate dehydrogenase to generate NADPH and therefore a spectrophotometric readout
6at 340 nm (Figure 2). Under these circumstances, in the presence of 6.33 mM Ap4A, no
significant change in absorbance could be detected. However, on addition of 0.1 mM ATP,
there was an instantaneous increase in absorbance consistent with the concentration of ATP
in the assay. This suggested that the coupling system could adequately discriminate
between ATP and Ap4A and was not significantly inhibited by the dinucleotide.
We then tested the ability of E. coli AlaRS, E. coli ValRS and E. coli IlelRS to catalyse
ATP production from Ap4A and investigated the dependence of this process on the presence
of the synthetase, the cognate amino acid and pyrophosphate. All three enzymes showed
linear Ap4A, pyrophosphate, synthetase and amino acid dependent production of ATP as an
increase in absorbance at 340nm over the rate measured in the absence of any one of these
components (Figure 3a-c).
To prove that the assay followed the pyrophosphorolytic cleavage of Ap4A we
followed a time course of the complete consumption of the diadenosine nucleotide by
S.pneumoniae AlaRS in the presence of L-alanine and excess pyrophosphate. We
observed that by the end point of the reaction, two equivalents of ATP were produced per
equivalent of Ap4A (Figure 3d). This was consistent with the stoichiometry of the cleavage of
Ap4A by pyrophosphate.
The reaction scheme of amino acid-dependent AaRS catalysed pyrophosphorolysis
of Ap4A indicated that the reaction would not be limited by the concentration of the amino
acid which is regenerated per catalytic cycle (Figure 2). Therefore, we performed assays
with IleRS at a limiting (10 PM) concentration of L-isoleucine. The absorbance of the assay
at 340 nm extended beyond that expected where L-isoleucine was simply consumed (0.062
AU), to that consistent with consumption of the next limiting substrate in the assay
(pyrophosphate; Figure 3c).
7Characterization of AaRS Ap4A consumption kinetics suggest an elevated sensitivity
to detection of inhibitors. Having established that IleRS, ValRS and AlaRS catalysed the
pyrophosphorolysis of Ap4A to two equivalents of ATP, we characterised the kinetics of L-
amino acid, pyrophosphate and Ap4A utilization by E. coli IleRS, ValRS and AlaRS. For all
three enzymes, dependence of activity on Ap4A, amino acid and pyrophosphate was strictly
hyperbolic (Figure S3a-i). Fitting the data to the Michaelis Menten equation generated the
kinetic constants for the dependence of activity of these enzymes on their substrates in the
Ap4A assay (Table 1).
Comparison of ADPNP and Ap4A based assays (Tables 1 and S1, Figures S2h and
S3h) revealed that for the E. coli AlaRS, the KmApp for Ap4A (0.87 ± 0.17 mM) was 181-fold
greater than that for ADPNP (4.8 ± 0.64 PM). Comparison of the data in Table 1 and Figure
S3h, S3b and S3e with previous 32P-pyrophosphate exchange measurements with cognate
amino acids suggested that the KmApp of E. coli AlaRS, IleRS and ValRS for Ap4A was 16.8-
fold27, 45.2-fold28 and 19.4-fold29 greater than for ATP. This suggested that Ap4A utilization
afforded the convenience of a continuous non-radioactive assay, and also endowed
synthetase assays with kinetic constants that would be more sensitive to inhibitor detection
than if assays utilised ATP as the adenylate substrate.
The data in Table 1 and Figure S3f and i also demonstrate that the KmApp values in
the Ap4A assay for the cognate amino acids for ValRS and AlaRS were in the high millimolar
range (14.22 ± 1.54 mM and 12.64 ± 1.86 mM respectively) where previously, values in the
ATP/pyrophosphate exchange reaction were 0.14 mM30 and 0.18 mM27. The increase in the
IleRS KmApp for L-isoleucine in the Ap4A assay (37.04 ± 3.17 µM; Table 1, Figure S3c)
relative to that previously published (4 µM31); was less marked, but nevertheless significant.
The 101-fold, 70.2-fold and 9.26-fold increase in amino acid KmApp for the ValRS, AlaRS and
IleRS respectively may have resulted from a reduced affinity of the amino acid for
synthetases bound to Ap4A. Similarly as concluded from the dependence of rates on Ap4A,
8the sensitivity of assays to the detection of amino acid or aminoacyl-adenylate synthetase-
targeted inhibitors would be expected to be vastly enhanced by the relatively high KmApp
values shown by these enzymes for their cognate amino acids.
The Ap4A assay applied to analysis of AaRS chemical and stereochemical amino acid
specificity. ValRS32, IleRS32 and AlaRS33 form adenylates and aminoacyl-tRNA species
with non-cognate amino acids. We therefore tested the ability of these enzymes to utilise
Ap4A as a substrate with L-threonine, L-serine and L-valine, the respective non-cognate
editing substrates of these enzymes32,33.
The Ap4A-activation of L-valine by IleRS and L-serine by S. pneumoniae AlaRS was
easily detectable (Figure 4 and Figure S4). Here, the efficiencies reported by relative
kcatApp/KmApp values of L-valine and L-isoleucine activation by E. coli IleRS (Table 1) were
1:206.3 which is in excellent agreement with previous measurement of 1:200 for this
parameter using 32P-pyrophosphate exchange34 and consistent with the requirement of
editing mechanisms by IleRS. However, consumption of Ap4A by ValRS was barely
detectable in the presence of 15 mM of its non-cognate L-threonine substrate. It is probable
that the impact of a reduced affinity for both non-cognate amino acid and the substitution of
ATP by Ap4A on catalysis was sufficient to severely reduce observable ValRS activity.
The utilization of Ap4A by IleRS and ValRS allowed us to extend our studies to the
utilization of D-isoleucine and D-valine by these enzymes. In this assay, D-valine did not
support ValRS activity, consistent with the previously noted stereo-specificity of this
enzyme35,36. Similarly, D-valine was not subject to non-cognate activation by IleRS, again,
consistent with previous observations37.
In contrast, D-isoleucine was activated by IleRS in the presence of Ap4A (Figure 4).
Comparison of relative efficiencies of activation suggested that IleRS was only 185.4-fold
more efficient with L-isoleucine as opposed to D-isoleucine, caused principally by a 110.5-
9fold increase in KmApp (Table 1). This level of discrimination is similar to that between L-
isoleucine and L-valine which has required the evolution of both post and pre-transfer editing
domains to eliminate erroneous incorporation of L-valine at L-isoleucine codons9-14,32,34.
Previous attempts37 to demonstrate D-isoleucine utilization by IleRS were not successful,
however, these assays were performed with a limit of detection of >1% the rate with cognate
L-isoleucine37, and as we have demonstrated here, although significant, the efficiency of the
enzyme with D-isoleucine is less than ~0.5% of that with L-isoleucine.
How mis-activation of D-isoleucine by IleRS is subsequently dealt with is of current
interest, as this D-amino acid and others are found naturally in the peptidoglycan of
stationary phase bacterial cultures38. This raises the possibility that formation of D-isoleucyl-
tRNAIle may challenge the stereochemical fidelity of protein synthesis, a possibility made
more likely by our inability to demonstrate any editing activity with respect to D-isoleucine
utilization by E. coli IleRS (Lloyd unpublished data).
Aminoacyl-adenylate mimetics suggest a possible multi-targeted approach to
inhibition of AaRSs. To further validate the Ap4A assay, we used a series of standard
synthetase inhibitors that mimic the aminoacyl-adenylate intermediates of AaRS activity
(Figure 5). Mupirocin acts as a tight binding analogue of isoleucyl-adenylate3-5. In the
Ap4A assay, mupirocin was a potent IleRS inhibitor (Figure 3c) with an IC50 of 0.35 ± 0.06
µM (Figure 5a) approximating to half the concentration of IleRS (1.13 µM) confirming the
tight-binding nature of this inhibitor. Conversely, mupirocin was a weak ValRS inhibitor
(37% at 0.5 mM), consistent with the specificity of the drug towards prokaryotic IleRS.
The aminoacyl-5’-sulphamoyl adenosines are potent AaRS inhibitors39 and E. coli
AlaRS was inhibited by alanyl-5’-sulphamoyl adenosine (Figure 3a) with an IC50 of 0.403 ±
0.005 µM (Figure 5b). The impact of cognate adenylate analogues on their cognate AaRSs
as shown here with AlaRS and IleRS confirmed the utility of the Ap4A assay. It is known that
ten of the AaRSs mis-activate non-cognate amino acids to their corresponding adenylates
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and require editing mechanisms to preserve the genetic code9,11,13. This suggested that if
the same amino acid was mis-activated by multiple synthetases, then a non-hydrolysable
mimic of its aminoacyl-adenylate may target these AaRSs as well as its cognate synthetase.
L-Threonine is mis-activated by ValRS which has editing mechanisms preventing the
mis-threonylation of tRNAVal 32. We therefore surmised that ValRS might be inhibited by the
non-cognate adenylate analogue threonyl-5’-sulphamoyl adenosine. This indeed was the
case (Figure 3b) and we further found in the Ap4A assay that ValRS was inhibited by this
compound with an IC50 of 6.82 ± 0.77 µM (Figure 5c). This suggested threonyl-5’-
sulphamoyl adenosine could multiply target noncognate ValRS and cognate ThrRS. This
was confirmed with the ADPNP/pyrophosphate exchange assay which showed that threonyl-
5’-sulphamoyl adenosine inhibited S. pneumoniae ThrRS with an IC50 of 0.175 ± 0.019 PM
(Figure 5c). The 38-fold greater potency of threonyl-5’-sulphamoyl adenosine towards
ThrRS relative to ValRS is likely to mirror at least in part the substrate specificities of these
two synthetases.
To further investigate the multi-targeting of AaRSs, we explored the inhibitory
properties of the seryl-adenylate analogue seryl-5’-sulphamoyl adenosine. Seryl-adenylate
is formed by the adenylation of L-serine by SerRS, and mis-adenylation by AlaRS and
ThrRS14,33,40. Using the S. pneumoniae enzymes we showed that (a) SerRS was inhibited
by seryl-5’-sulphamoyl adenosine with an IC50 of 0.44 ± 0.076 PM (Figure 5d); (b) AlaRS
was inhibited with an IC50 of 0.133 ± 0.046 PM (Figure 5d) and (c) ThrRS was inhibited with
an IC50 of between 5 and 50 PM (Figure S5a). Interestingly, alanyl-5’-sulphamoyl adenosine
was not an inhibitor of SerRS (Figure S5b), consistent with the requirement by this enzyme
for the E-hydroxyl of L-serine for amino acid recognition23. None of these inhibitors affected
the activity of the hexokinase/glucose 6 phosphate dehydrogenase coupling system.
Interestingly, the overlapping potency of the above aminoacyl adenylate mimetics are
consistent with the overlapping amino acid substrate specificity of these three
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synthetases9,11,13,33,40 and may explain the extremely high potency of sideromycins such as
albomycin, a natural pro-drug antibiotic that releases a cleavable warhead comprising a seryl
adenylate analogue41 on entry into the target bacterial cell. Our data suggest that this
warhead could simultaneously deprive protein synthesis of seryl-tRNASer, alanyl-tRNAAla and
threonyl-tRNAThr.
Our data suggest that multiple AaRSs that share the formation of a cognate or non-
cognate aminoacyl adenylates could be targeted by a single inhibitor. Indeed, alanyl-5’
sulphamoyl adenosine is a nanomolar inhibitor of not only AlaRS but also of E. coli prolyl-
tRNAPro synthetase42. Multi-targeting of a molecule to multiple essential gene products is
attractive for antimicrobial development because of the additional hurdles it presents to the
development of resistance43. Therefore, development of multi-targeted AaRS inhibitors
using for example seryl-adenylate analogues as a starting point may allow development of
novel antimicrobials which are robust with respect to the evolution of resistance.
Assessment of the Ap4A assay in the screening for AaRS inhibitors. The original
motivation for the development of the Ap4A assay was to assess the inhibitory properties of
molecules selected or designed as a result of in silico drug design. This required an assay
whose sensitivity to competitive inhibitors was enhanced by virtue of utilization of substrates
that possessed a low affinity for the enzyme.
We employed in silico drug design by SPROUT44 to identify small molecules that
could bind to the aminoacyl-adenylate binding pockets of both E. coli IleRS and ValRS.
Cognisant of our Ap4A kinetic data regarding the substrate dependences of these
synthetases, we configured assays at sub-saturating amino acid and Ap4A concentrations to
optimise the sensitivity of the assay to inhibitors competitive with respect to the amino acid,
ATP and aminoacyl-adenylate binding sites. For IleRS these were (Concentration/
Concentration relative to KmApp) Ap4A: 0.7 mM/0.11.KmApp, L-isoleucine: 10 PM/0.27.KmApp
and pyrophosphate: 20 PM/6.43.KmApp. Similarly, for ValRS these were Ap4A: 0.388
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mM/0.20.KmApp, L-valine: 4 mM/0.32.KmApp and pyrophosphate: 20 PM/8.23.KmApp. Typical
rates measured under these circumstances for both enzymes are shown in Figure 3b,c.
Under these conditions, the standard deviation of the assays for both enzymes
expressed as a percentage of the mean value for a triplicate determination of initial rate was
7.0 % (range, 2.4% - 9.2% n = 7) for IleRS and 4.8 % (range, 1.7% - 8.1% n = 10) for ValRS.
Assuming a positive identification of an inhibitor was a drop in measured activity of at least
three standard deviations and competitive kinetics, these assays would detect IleRS
inhibitors competitive with L-isoleucine, Ap4A and pyrophosphate with KiYDOXHVP0
 P0 DQG   P0 UHVSHFWLYHO\ DW D VHW LQKLELWRU FRQFHQWUDWLRQ RI  P0  6LPLODUO\
ValRS inhibitors competitive with L-valine, Ap4A and pyrophosphate with KiYDOXHVP0
P0DQGP0UHVSHFWLYHO\ZRXOGEHH[SHFWHGWREHGHWHFWHG
We assessed the signal:noise ratio of the assay (the ratio of rates with and without
pyrophosphate). For IleRS and ValRS, the signal to noise ratios of the assays at the
concentration of the enzyme used in screening (2.25 PM and 2.21 PM respectively) were
3.86 ± 1.15 (n= 35 positive controls) and 7.79 ± 2.14 (n = 30 positive controls) respectively.
We further characterised the ability of the assay to discriminate between the
presence and absence of standard inhibitors. The Z’ values45 for the IleRS assay with
respect to inhibition by 5 PM mupirocin and the ValRS assay with respect to inhibition by 50
PM threonyl-5’-sulphamoyl adenosine were 0.84 and 0.792, suggesting excellent
discrimination between positive and negative control assays.
With the assay thus configured, we screened a library of 73 compounds against both
enzymes. Although we were unable to identify novel dual targeted inhibitors in this manner,
we identified two IleRS inhibitors: N-tert-Butyl-2-(3-{[3-(tert-butylcarbamoyl-methyl)benzyl-
amino]-methyl}-phenyl)-acetamide (195) and N-Isopropyl-2-(3-{[3-(isopropyl-carbamoyl-
methyl)-benzylamino]-methyl}-phenyl)-acetamide (202) exerting 82.2 and 75.3% inhibition at
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1 mM with Z-factors of 0.73 and 0.55 and IC50 values on re-screening of 0.22 ± 0.035 mM
and 0.895 ±0.057 mM respectively (Figure 6a and b). These molecules exerted no effect on
the hexokinase/6-phospho-gluconate dehydrogenase coupling system, nor were they
inhibitors of ValRS.
Both 195 and 202 were competitive inhibitors against L-isoleucine and Ap4A with Ki
values for 195 vs Ap4A and L-isoleucine of 0.14 and 0.184 mM respectively and for 202 vs
Ap4A and L-isoleucine of 0.792 and 0.398 mM respectively (Figures 6c-f). This suggested
that they bound to IleRS at the site they were targeted to (Figures 6c-f). The Ki values
suggested weak binding for these inhibitors to IleRS, compared to the inhibitors already
discussed, but are consistent with the starting point for fragment based drug design46.
Screening of this library with ValRS identified HTS026477 (4-Amino-2-[2-oxo-2-(3-
phenyl-isoxazol-5-yl)ethylsulfanyl]-pyrimidine-5-carboxylic acid)) that was not an IleRS
inhibitor. This molecule exerted 62.8% inhibition (Z’ factor = 0.74) and on re-screening
displayed a sigmoid dependence of inhibition on concentration (IC50 = 1.51 ± 0.32 mM, Hill
coefficient of 3.65 ± 0.68; Figure 7d)). Although we did not characterise the interaction of
HTS026477 with ValRS further, to gain additional insight into molecules that might bring
about inhibition of this enzyme, we identified a series of triazinyl dyes that inhibited the
enzyme, based on our and previous observations regarding ValRS purification with
immobilised dyes47. These dyes were Procion Red HE-3B, Procion Green HE4BD and
Trypan Blue. IC50 values for these compounds were 2.14 ± 0.29 PM, 6.98 ± 1.23 PM and
19.2 ± 8.6 PM respectively (Figures 7a-c).
Interestingly, Procion Green HE4BD inhibits Bacillus stearothermophilus methionyl-
tRNAMet synthetase48 suggesting that this dye could provide a starting point for the
development of multi-targeted AaRS inhibitors. Trypan blue has anti-trypanosomal activity,
targeting the glycolytic pathway49 and is used in the treatment of trypanosomiasis. Our data
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suggest that this molecule may also interfere with protein synthesis by targeting ValRS,
which itself may be a viable strategy in treatment of this disease.
These data highlight the capability of Ap4A based assays to analyse binding events
to synthetases from nM to mM affinities and exemplify the utility of this assay in fundamental
and translational AaRS research.
Finally, the potential utility of this assay is greater than that reported here. Many
drug targets turnover Ap4A, and we are currently pursuing assay development for these
enzymes50. Furthermore, NADPH utilization as a reporter of enzyme activity suggests an
additional fluorescence format for these assays, whilst the exploitation of Ap4A to generate
ATP indicates the potential for linking Ap4A consumption to a fire-fly luciferase based
luminescence readout.
Methods
E. coli AlaRS, IleRS, and ValRS and S. pneumoniae AlaRS, SerRS, and ThrRS were
expressed as C-terminal hexahistidine fusion proteins and were purified as described51.
Purification of ValRS was completed by chromatography on Sepharose-4B coupled to
Procion Green HE4BD to eliminate contamination with inorganic pyrophosphatase.
Leuconostoc mesenteroides glucose 6 phosphate dehydrogenase and yeast hexokinase
were obtained from Roche. Alanyl-, threonyl and seryl-5’-sulphamoyl adenosines were from
IDT, Ap4A was from Sigma. All other reagents were from Sigma or Melford.
AaRS assays were performed at 37ºC in a Cary 100 UV/Vis double beam
spectrophotometer with a thermostatted 6X6 cell changer. The final assay volume was 0.2
ml, containing 50 mM HEPES adjusted to pH 7.6, 10 mM MgCl2, 50 mM KCl, 1 mM
dithiothreitol, 10% (v/v) dimethylsulphoxide, 10 mM D-glucose, 0.5 mM NADP+, 1.7 mM.min
L. mesenteroides hexokinase and 0.85 mM.min L. mesenteroides glucose 6-phosphate
dehydrogenase. Concentrations of AaRS, amino acid, adenylate (Ap4A or ADPNP) and
15
pyrophosphate were as stated in the text. Unless otherwise stated, background rates were
acquired in the absence of pyrophosphate, which was then added to initiate the full reaction.
Assays were continuously monitored at 340 nm, to detect reduction of NADP+ to NADPH,
where HNADPH; 340nm = 6220 M-1.cm-1.
Kinetic constants relating to substrate dependencies and IC50 values for inhibitors
were extracted by non-linear regression using GraphPad Prizm. Modes of inhibition and Ki
values were evaluated by linear regression of dependencies of reciprocal velocity on
reciprocal substrate concentration at varying inhibitor concentration.
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Table Legends
Table 1: Characterization of the kinetics of substrate dependence of E. coli AlaRS,
IleRS and ValRS on the rate of pyrophosphorolysis of Ap4A
Figure Legends
Figure 1. Catalytic activities of AaRSs. Formation of the central aminoacyl-adenylate
intermediate and inorganic pyrophosphate from ATP and an amino acid14, and
reactions of this intermediate with the C-2 or C-3 hydroxyl of the 3’ ribose of the
cognate tRNA (reaction 2) forms an aminoacyl-tRNA. In the absence of tRNA the
adenylate intermediate can be cleaved by an alternative nucleophile which can be
pyrophosphate (reaction 1) which attacks the D-phosphorus atom of the aminoacyl
adenylate displacing the amino acid and regenerating ATP, or the oxygen atom
appended to the J-phosphorus of a second molecule of ATP which attacks the D-
phosphorus of the adenylate moiety of the aminoacyl adenylate (reaction 3). This
results in the amino acid-dependent formation of diadenosine 5’,5’’’ P1 P4
tetraphosphate (adenosine tetraphospho-adenosine (Ap4A)).
Figure 2. Reversal of Ap4A synthesis by AaRS. Cleavage of Ap4A by an amino acid
substrate and pyrophosphate yielding two molecules of ATP which can be
continuously monitored by coupling to NADP+ reduction to NADPH.
Figure 3: Time courses of AaRS-catalysed amino acid dependent pyrophosphorolysis
of Ap4A to ATP. PPi denotes pyrophosphate. Background rates were followed
before addition of the missing component of the assay at arrow. Panel (a): E. coli
AlaRS activity, in the presence of 0.41 mM Ap4A, 2 mM L-alanine, 20 PM
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pyrophosphate and 0.92 PM AlaRS; Panel (b) E. coli ValRS activity, in the
presence of 0.388 mM Ap4A, 4 mM L-valine, 20 PM pyrophosphate and 2.41 PM
ValRS; Panel (c) E. coli IleRS activity, in the presence of 0.7 mM Ap4A, 10 PM L-
isoleucine, 20 PM pyrophosphate and 2.4 PM ValRS. For panels (a) - (c) assays
were run without (maroon trace, DMSO control) or with 5 PM alanyl-5’-sulphamoyl
adenosine (ASA), 50 PM threonyl-5’-sulphamoyl adenosine (TSA) or 5 PM mupirocin
(blue trace). Panel (d): Stoichiometry of conversion of Ap4A to ATP in the presence
of L-alanine and S. pneumoniae AlaRS. Reaction was allowed to approach
equilibrium in the presence of 1.8 PM AlaRS, 0.471 mM pyrophosphate and 27.2 PM
Ap4A. Final [ATP] inferred from the 'A340 on completion of the reaction was 59.2 PM,
implying conversion of Ap4A to 2.16 equivalents of ATP.
Figure 4: Impact of chemical and stereochemical identity on the dependence of initial
rate of IleRS on amino acid substrate. Assays were performed at co-substrate
and enzyme concentrations recorded in Table 1. Data were fitted to the Michaelis
Menten equation using GraphPad Prizm yielding the kinetic constants shown in
Table 1.
Figure 5: Validation of the Ap4A AaRS assay and identification of single and multiply
targeted aminoacyl adenylate analogue inhibitors. Panel (a): Dependence of
inhibition of IleRS on mupirocin in the presence of 1.13 µM IleRS, 2 mM Ap4A, 14.4
mM L-isoleucine and 0.471 mM pyrophosphate; Panel (b): Dependence of inhibition
of E. coli AlaRS on alanyl-5’-sulphamoyl adenosine, conditions as described in the
Figure 3a; Panel (c): Dependence of inhibition of E. coli ValRS and S. pneumoniae
threonyl-tRNAThr synthetase (ThrRS) on threonyl-5’-sulfamoyl adenosine where 1.14
PM ValRS was assayed in the presence of 2 mM Ap4A, 14.4 mM L-valine and 0.471
mM pyrophosphate (rust) and 0.132 PM ThrRS was assayed as described for
assays containing Ap4A except 0.5 mM ADPNP was substituted for Ap4A and L-
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threonine and pyrophosphate were10 mM and 0.118 mM respectively (dark blue);
Panel (d):, Dependence of inhibition of S. pneumoniae AlaRS and SerRS on seryl-
5’-sulfamoyl adenosine, where for both enzymes ADPNP and pyrophosphate were
0.25 mM and 0.471 mM respectively, and assays contained either 2.08 PM SerRS
and 0.2 mM L-serine (blue) or 0.21 PM AlaRS, and 0.2 mM L-alanine (rust). Inhibitor
structures are in pale yellow boxes.
Figure 6: Evaluation of the inhibitory properties of compounds 195 and 202, IleRS
inhibitors identified by screening with the Ap4A assay. All data were collected at
3.14 PM IleRS. Panels (a) and (b) show dependence of inhibition of IleRS on either
compound 195 or 202 respectively. [Ap4A], [L-isoleucine] and [pyrophosphate] were
0.7 mM, 10 PM, and 20 PM respectively. Panels (c) and (d) are reciprocal plots of
IleRS activity at increasing concentrations of L-isoleucine in the presence of 0-3
mM195 (c) or 0-3.6 mM 202 (d). Panels (e) and (f) are reciprocal plots of IleRS
activity at increasing concentrations of Ap4A in the presence of the same range of
195 (e) or 202 concentrations (f). [Pyrophosphate] in assays contributing to data in
Panels (c) to (f) was 20 PM. Inserts in panels (c) to (f) are secondary plots of slopes
of reciprocal plots vs. [inhibitor]. Ki values were determined from the abscissa
intercept of secondary plots.
Figure 7: Characterization of ValRS inhibitors identified by the Ap4A assay: [ValRS],
[Ap4A], [pyrophosphate] and [L-valine] were 2.21 PM, 0.388 mM, 32 PM and: 4 mM
respectively. Inhibition of ValRS by: Panel (a) Procion Red HE3B; Panel (b)
Procion Green HE4BD; Panel (c) Trypan Blue and; Panel (d) HTS 02677. None of
these compounds significantly inhibited IleRS, nor exerted significant inhibition of the
hexokinase/6phosphogluconate dehydrogenase coupling system.
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Table 1
AaRS [AaRS]Assay Nonvaried
substrate
[Nonvaried
substrate]
(mM)
Varied
Substrate
KmApp
(PM)
kcatApp
(min-1)
kcatApp/KmApp
(min-1.PM-1)
AlaRS
0.92 PM L-Alanine 10.00 L-Alanine 14220 ± 1540 39.3 ± 1.93 0.0028
0.92 PM Ap4A 3.99 Ap4A 871 ± 171 21.85 ± 1.16 0.0251
0.92 PM PPi 0.471 PPi 12.81 ± 1.62 19.62 ± 0.79 1.531
IleRS
1.13 PM L-
Isoleucine
14.4 L-Isoleucine 37.04 ± 3.17 6.99 ± 0.18 0.1887
1.13 PM Ap4A 5.00 Ap4A 6330 ± 930 16.51 ± 1.29 0.00261
1.13 PM PPi 0.471 PPi 3.11 ± 0.52 7.70 ± 0.36 2.476
0.74 PM L-Valine 3955 ± 694 3.671 ± 0.198 0.00093
0.74 PM D-Isoleucine 4095 ± 394 4.169 ± 0.167 0.00102
ValRS
1.10 PM L-Valine 14.4 L-Valine 12640 ± 1860 10.06 ± 0.87 0.00080
1.10 PM Ap4A 1.53 Ap4A 1940 ± 194 9.96 ± 0.426 0.00513
1.10 PM PPi 0.471 PPi 2.43 ± 2.13 4.71 ± 0.086 1.938
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Supporting Table Legend
Table S1: Characterization of the kinetics of substrate dependence of E. coli AlaRS, S.
pneumoniae AlaRS and S. pneumoniae SerRS on the rate of pyrophosphorolysis of
ADPNP
Supporting Figure Legends
Figure S1 Assay of AaRS activity by coupling pyrophosphate exchange in the
presence of ADPNP: (a) Reaction scheme of the ADPNP assay where the AaRS
catalyses the attack of the amino acid D-carboxyl on the D-phosphorus atom of ADPNP,
forming an aminoacyl adenylate and liberating imidodiphosphate as the first product.
Addition of pyrophosphate to the assay displaces the amino acid and forms ATP as a
second product which can then be detected spectrophotometrically at 340 nm by coupling to
33
hexokinase and glucose 6 phosphate dehydrogenase. (b) Limited utility of ADPNP in the
assay of AaRS pyrophosphate exchange. Time courses of the assay of ValRS, IleRS and
SerRS in the ADPNP assay, where at time zero, all assays were constituted as described in
Methods such that in the SerRS, IleRS and ValRS assays [ADPNP] was 0.1 mM, 1 mM and
1 mM respectively; [L-serine], [L-ilsoleucine] and [L-valine] were 0.4 mM, 2.4 mM and 2.5
mM respectively and [SerRS], [IleRS] and [ValRS] were 1.21 PM, 2.29 PM and 0.54 PM
respectively. Background rates were monitored at 340 nm and assays were initiated by the
addition of either 0.1 mM, 0.0834mM or 0.0834 mM pyrophosphate to the SerRS, IleRS and
ValRS assays respectively at, a, b or c respectively.
Figure S2 Dependence of E. coli AlaRS, S. pneumoniae AlaRS and SerRS on ADPNP,
pyrophosphate and cognate amino acid. All assays were executed as described in
Methods, where assays were initiated with pyrophosphate and initial velocity (v0) was
obtained from the difference of rates obtained post and pre-addition of pyrophosphate.
When held constant, the concentrations of pyrophosphate, ADPNP and L-amino acid were
as reported in Table S1. For all determinations of dependence of v0 on [substrate], the
[enzyme] is recorded in Table S1. Panel a – c : Dependence of S. pneumoniae SerRS
on [pyrophosphate], [ADPNP] and [L-serine]; Panel d – f : Dependence of S.
pneumoniae AlaRS on [pyrophosphate], [ADPNP] and [L-alanine]; Panel g – i :
Dependence of E. coli AlaRS on [pyrophosphate], [ADPNP] and [L-alanine]. Kinetic
constants were determined by non-linear regression and are recorded in Table S1.
Figure S3 Dependence of E. coli AlaRS, IleRS and ValRS on Ap4A, pyrophosphate and
cognate amino acid. All assays were executed as described in Methods, where assays
were initiated with pyrophosphate and v0 was obtained from the difference of rates obtained
post and pre-addition of pyrophosphate. When held constant, the concentrations of
pyrophosphate, Ap4A and L-amino acid were as reported in Table 1. For all determinations
of dependence of v0 on [substrate], the [enzyme] is recorded in Table 1. Panel a – c :
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Dependence of IleRS on [pyrophosphate], [Ap4A] and [L-isoleucine]; Panel d – f :
Dependence of ValRS on [pyrophosphate], [Ap4A] and [L-valine]; Panel g – i :
Dependence of E. coli AlaRS on [pyrophosphate], [Ap4A] and [L-alanine]. Kinetic constants
were determined by non-linear regression and are recorded in Table 1.
Figure S4 Time course of S. pneumoniae AlaRS catalysed pyrophosphorolysis of
Ap4A with non-cognate L-serine. Assay was as outlined in Methods, where the final
concentrations of AlaRS, L-serine, Ap4A and pyrophosphate were 0.70 PM, 10 mM, 2 mM
and 0.471 mM respectively. All components except AlaRS and L-serine were present at
time zero. S. pneumoniae AlaRS and L-serine were added as indicated. Progress of the
reaction was followed at 340 nm.
Figure S5 Inhibition of AaRSs by aminoacyl-sulphamoyl adenylates: (a) Inhibition of
S. pneumoniae ThrRS by seryl sulphamoyl adenosine. Figure shows ThrRS rates in the
presence of increasing [seryl-5’-sulphamoyl adenosine] (abbreviated to SSA in figure).
Assays were carried out as described in Methods, where [pyrophosphate], [ADPNP], [L-
threonine] were 0.471 mM, 0.254 mM and 10 mM respectively. [ThrRS] was at 0.55 PM.
Background data were collected until 2.4 min, when the assays were initiated by the addition
of L-threonine (arrow). Assays were performed in the presence of 0, 5PM, 50 PM and 500
PM seryl-5’-sulphamoyl adenosine. The % inhibition caused by increasing seryl-5’-
sulphamoyl adenosine is recorded adjacent to the traces as % I. (b) Specificity of
inhibition displayed by SerRS for seryl-5’-sulphamoyl adenosine compared to alanyl-
5’-sulphamoyl adenosine. Figure shows aminoacyl-specificity of inhibition of S.
pneumoniae SerRS by cognate seryl-5’-sulphamoyl adenosine and non-cognate alanyl-5’-
sulphamoyl adenosine. Assays were performed as described in Methods where
[pyrophosphate], [ADPNP] and [L-serine] were 1 mM, 0.250 mM and 0.2 mM respectively.
[SerRS] was at 2.08 PM. Assays were initiated by the addition of L-serine and performed at
35
concentrations of alanyl-5’-sulphamoyl adenosine (red) and seryl-5’-sulphamoyl adenosine
(blue).
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Table S1
AaRS Species [AaRS]Assay Nonvaried
substrate
[Nonvaried
substrate]
(mM)
Varied
Substrate
KmApp
(PM)
kcatApp
(min-1)
KcatApp/kmApp
(min-1.PM-1)
AlaRS
E. coli
0.37 PM L-Alanine 0.200 L-Alanine 1418 ± 68 78.24 ± 1.14 0.0552
0.92 PM ADPNP 0.243 ADPNP 4.8 ± 0.64 9.384 ± 0.24 1.955
0.92 PM PPi 0.471 PPi 24.89 ± 2.66 7.038 ± 0.24 0.283
S. pneumoniae
0.21 PM L-Alanine 0.200 L-Alanine 1770 ± 220 118.2 ± 3.0 0.0667
0.21 PM ADPNP 0.254 ADPNP 12.82 ± 1.77 13.26 ± 0.48 1.030
0.17 PM PPi 0.471 PPi 22.68 ± 2.78 13.20 ± 0.72 0.582
SerRS S. pneumoniae
2.08 PM L-Serine 0.200 L-Serine 527 ± 64 1.86 ± 0.06 0.0035
12.14 PM ADPNP 0.254 ADPNP 107.2 ± 12.7 0.467 ± 0.0074 0.0044
12.14 PM PPi 0.471 PPi 56.35 ± 6.96 0.420 ± 0.018 0.0075
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